Evgen Pharma PLC’s (EVG) “Speculative Buy” Rating Reaffirmed at Beaufort Securities
Separately, Northland Securities reiterated a buy rating and issued a GBX 97 ($1.18) price objective on shares of Evgen Pharma PLC in a report on Thursday, September 15th.
Shares of Evgen Pharma PLC (LON:EVG) traded down 4.08% during midday trading on Thursday, reaching GBX 23.50. 24,202 shares of the company were exchanged. Evgen Pharma PLC has a 52-week low of GBX 14.50 and a 52-week high of GBX 35.00. The company’s 50-day moving average price is GBX 23.12 and its 200 day moving average price is GBX 22.67. The stock’s market capitalization is GBX 17.19 million.
COPYRIGHT VIOLATION NOTICE: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this report can be read at http://www.dailypolitical.com/2017/01/13/evgen-pharma-plcs-evg-speculative-buy-rating-reaffirmed-at-beaufort-securities.html.
About Evgen Pharma PLC
Evgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane.
Receive News & Ratings for Evgen Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.